

Supplementary Table S1 Geographic distribution of patients with different races

| | White | Arab | Asian | Black |
|--------------------|---------------------|------------------|------------------|------------------|
| Patients, N | 40,258 | 995 | 689 | 264 |
| Europe | 37,635 (94%) | 299 (30%) | 107 (16%) | 155 (59%) |
| Spain | 30,973 (77%) | 236 (24%) | 75 (11%) | 120 (45%) |
| Italy | 3,412 (8.5%) | 14 (1.4%) | 18 (2.6%) | 12 (4.6%) |
| Latvia | 751 (1.9%) | 0 | 1 (0.1%) | 0 |
| France | 415 (1.0%) | 40 (4.0%) | 5 (0.7%) | 18 (6.8%) |
| Belgium | 417 (1.0%) | 1 (0.1%) | 1 (0.1%) | 1 (0.4%) |
| Switzerland | 386 (1.0%) | 6 (0.6%) | 4 (0.6%) | 4 (1.5%) |
| Portugal | 328 (0.8%) | 1 (0.1%) | 2 (0.3%) | 0 |
| Germany | 274 (0.7%) | 0 | 0 | 0 |
| Macedonia | 256 (0.6%) | 1 (0.1%) | 0 | 0 |
| Czech Republic | 192 (0.5%) | 0 | 1 (0.1%) | 0 |
| Austria | 173 (0.4%) | 0 | 0 | 0 |
| Other countries | 58 (0.1%) | 0 | 0 | 0 |
| Americas | 480 (1.2%) | 1 (0.1%) | 21 (3.0%) | 83 (31%) |
| United States | 418 (1.0%) | 1 (0.1%) | 13 (1.9%) | 66 (25%) |
| Colombia | 1 (0%) | 0 | 0 | 0 |
| Argentina | 43 (0.1%) | 0 | 1 (0.1%) | 0 |
| Brazil | 6 (0.01%) | 0 | 7 (1.0%) | 10 (3.8%) |
| Ecuador | 0 | 0 | 0 | 7 (2.7%) |
| Honduras | 0 | 0 | 0 | 0 |
| Canada | 12 (0.03%) | 0 | 0 | 0 |
| Bolivia | 0 | 0 | 0 | 0 |
| Asia | 2,139 (5.3%) | 682 (69%) | 561 (81%) | 11 (4.2%) |
| Israel | 1,750 (4.3%) | 681 (69%) | 1 (0.1%) | 11 (4.2%) |
| Iran | 388 (1.0%) | 1 (0.1%) | 65 (9.4%) | 0 |
| Vietnam | 1 (0%) | 0 | 438 (64%) | 0 |
| Japan | 0 | 0 | 46 (6.7%) | 0 |
| China | 0 | 0 | 11 (1.6%) | 0 |
| Africa | 4 (0.01%) | 13 (1.3%) | 0 | 15 (5.7%) |
| Morocco | 4 (0.01%) | 11 (1.1%) | 0 | 15 (5.7%) |
| Egypt | 0 | 2 (0.2%) | 0 | 0 |

Supplementary Table S2 Univariate and multivariate analyses for recurrent PE and recurrent DVT

| | Recurrent PE | | Recurrent DVT | |
|---------------------------------|------------------|------------------|------------------|------------------|
| | Univariate | Multivariate | Univariate | Multivariate |
| Demographics | | | | |
| Female | 0.96 (0.80–1.16) | – | 0.76 (0.64–0.90) | 0.80 (0.67–0.96) |
| Age | 1.00 (0.99–1.00) | – | 0.98 (0.98–0.99) | 0.98 (0.97–0.99) |
| Weight | 1.00 (0.99–1.01) | – | 1.00 (0.99–1.00) | – |
| Initial VTE presentation | | | | |
| Pulmonary embolism | Ref. | – | Ref. | Ref. |
| Isolated DVT | 0.85 (0.70–1.03) | – | 2.03 (1.71–2.40) | 1.64 (1.37–1.96) |
| Comorbidities | | | | |
| Chronic lung disease | 1.48 (1.14–1.91) | 1.31 (1.00–1.70) | 0.87 (0.66–1.15) | – |
| Chronic heart failure | 1.69 (1.24–2.31) | 1.59 (1.15–2.18) | 0.61 (0.40–0.93) | 0.90 (0.58–1.41) |
| Hypertension | 1.09 (0.90–1.31) | – | 0.76 (0.64–0.90) | 1.10 (0.91–1.34) |
| Diabetes | 0.97 (0.75–1.25) | – | 1.05 (0.84–1.32) | – |
| Prior arterial disease | 1.22 (0.94–1.59) | – | 0.76 (0.58–1.00) | 0.93 (0.69–1.23) |
| Recent major bleeding | 1.69 (1.01–2.83) | 1.53 (0.91–2.57) | 1.64 (1.02–2.64) | 1.29 (0.80–2.10) |
| Risk factors for VTE | | | | |
| Active cancer | 2.20 (1.77–2.73) | 1.98 (1.58–2.49) | 2.71 (2.25–3.28) | 2.51 (2.00–3.15) |
| Other risk factors | 1.04 (0.82–1.31) | 0.99 (0.78–1.26) | 0.99 (0.79–1.24) | 0.97 (0.76–1.23) |
| Unprovoked | Ref. | Ref. | Ref. | Ref. |
| Prior VTE | 1.05 (0.81–1.37) | – | 1.31 (1.06–1.62) | 1.40 (1.12–1.73) |
| Blood tests | | | | |
| Anemia | 1.09 (0.89–1.33) | – | 1.59 (1.34–1.89) | 1.12 (0.92–1.37) |
| Thrombocytopenia | 1.29 (0.76–2.20) | – | 1.65 (1.08–2.52) | 1.13 (0.72–1.75) |
| CrCl levels <60 mL/min | 1.01 (0.82–1.25) | – | 0.63 (0.51–0.78) | 0.94 (0.75–1.19) |
| Concomitant drugs | | | | |
| Statins | 0.92 (0.73–1.14) | – | 0.87 (0.71–1.06) | – |
| Antiplatelets | 1.84 (1.32–2.55) | 1.62 (1.16–2.27) | 1.00 (0.69–1.47) | – |
| Corticosteroids | 1.35 (1.00–1.80) | 1.10 (0.82–1.48) | 1.07 (0.81–1.43) | – |
| Psychotropics | 0.98 (0.78–1.23) | – | 0.82 (0.66–1.02) | 1.02 (0.82–1.27) |
| Long-term therapy | | | | |
| DOACs | 0.55 (0.43–0.71) | 0.63 (0.49–0.82) | 0.57 (0.45–0.72) | 0.63 (0.50–0.80) |
| Geographic location | | | | |
| Europe | Ref. | – | Ref. | Ref. |
| Americas | 1.31 (0.65–2.64) | – | 1.95 (1.12–3.39) | 1.74 (0.99–3.09) |
| Asia/Africa | 0.94 (0.64–1.39) | – | 3.12 (2.48–3.92) | 2.24 (1.67–3.00) |
| Races | | | | |
| White | Ref. | Ref. | Ref. | Ref. |
| Arab | 1.04 (0.54–2.01) | 0.99 (0.51–1.92) | 2.91 (1.99–4.26) | 1.21 (0.77–1.91) |
| Asian | 0.62 (0.20–1.92) | 0.75 (0.24–2.35) | 2.93 (1.75–4.90) | 1.44 (0.82–2.52) |
| Black | 1.60 (0.60–4.30) | 1.79 (0.67–4.82) | 1.76 (0.73–4.27) | 1.09 (0.44–2.72) |

Note: Results are expressed as hazard ratios and 95% confidence intervals (in brackets).

Supplementary Table S3 Univariate and multivariate analyses for major bleeding and death

| | Major bleeding | | Death | |
|---------------------------------|------------------|------------------|------------------|------------------|
| | Univariate | Multivariate | Univariate | Multivariate |
| Demographics | | | | |
| Female | 1.16 (1.04–1.30) | 0.99 (0.88–1.12) | 1.05 (0.99–1.12) | – |
| Age | 1.03 (1.02–1.03) | 1.01 (1.01–1.02) | 1.04 (1.03–1.04) | 1.03 (1.03–1.03) |
| Weight | 0.99 (0.99–0.99) | 1.00 (1.00–1.01) | 0.97 (0.97–0.97) | 0.99 (0.98–0.99) |
| Initial VTE presentation | | | | |
| Pulmonary embolism | Ref. | Ref. | Ref. | Ref. |
| Isolated DVT | 0.67 (0.60–0.75) | 0.73 (0.65–0.83) | 0.73 (0.68–0.77) | 0.69 (0.64–0.74) |
| Comorbidities | | | | |
| Chronic lung disease | 1.47 (1.26–1.71) | 1.08 (0.92–1.27) | 1.73 (1.60–1.88) | 1.24 (1.13–1.35) |
| Chronic heart failure | 1.68 (1.40–2.01) | 1.08 (0.89–1.31) | 2.27 (2.07–2.50) | 1.55 (1.39–1.72) |
| Hypertension | 1.67 (1.50–1.87) | 1.18 (1.03–1.34) | 1.29 (1.21–1.38) | 0.86 (0.80–0.93) |
| Diabetes | 1.47 (1.28–1.67) | 1.09 (0.95–1.25) | 1.62 (1.50–1.74) | 1.25 (1.15–1.36) |
| Prior arterial disease | 1.54 (1.33–1.77) | 1.07 (0.92–1.24) | 1.88 (1.74–2.03) | 1.41 (1.29–1.55) |
| Recent major bleeding | 3.41 (2.75–4.24) | 2.39 (1.91–2.99) | 2.11 (1.81–2.47) | 1.16 (0.97–1.39) |
| Risk factors for VTE | | | | |
| Active cancer | 2.54 (2.21–2.90) | 1.80 (1.55–2.10) | 9.57 (8.85–10.4) | 6.45 (5.89–7.06) |
| Other risk factors | 1.80 (1.58–2.05) | 1.53 (1.33–1.75) | 2.19 (2.00–2.41) | 1.84 (1.67–2.04) |
| Unprovoked | Ref. | Ref. | Ref. | Ref. |
| Prior VTE | 0.75 (0.63–0.89) | 0.88 (0.74–1.05) | 0.65 (0.59–0.72) | 0.84 (0.75–0.93) |
| Blood tests | | | | |
| Anemia | 2.46 (2.20–2.74) | 1.77 (1.57–2.00) | 3.49 (3.27–3.71) | 1.61 (1.50–1.73) |
| Thrombocytopenia | 1.83 (1.40–2.39) | 1.33 (1.01–1.75) | 3.09 (2.73–3.50) | 1.61 (1.40–1.86) |
| CrCl levels <60 mL/min | 2.08 (1.86–2.32) | 1.37 (1.19–1.58) | 2.23 (2.10–2.37) | 1.23 (1.13–1.34) |
| Concomitant drugs | | | | |
| Statins | 1.24 (1.10–1.40) | 0.96 (0.84–1.09) | 0.90 (0.84–0.97) | 0.68 (0.63–0.74) |
| Antiplatelets | 1.18 (0.94–1.48) | – | 1.73 (1.55–1.94) | 1.04 (0.92–1.18) |
| Corticosteroids | 2.05 (1.77–2.38) | 1.50 (1.29–1.75) | 2.74 (2.53–2.96) | 1.74 (1.60–1.90) |
| Psychotropics | 1.51 (1.34–1.70) | 1.17 (1.03–1.32) | 1.49 (1.39–1.60) | 1.13 (1.05–1.22) |
| Long-term therapy | | | | |
| DOACs | 0.45 (0.38–0.53) | 0.57 (0.49–0.67) | 0.24 (0.21–0.27) | 0.34 (0.30–0.39) |
| Geographic location | | | | |
| Europe | Ref. | Ref. | Ref. | Ref. |
| America | 0.38 (0.18–0.80) | 0.48 (0.23–1.02) | 0.58 (0.41–0.82) | 0.73 (0.44–1.20) |
| Asia/Africa | 0.58 (0.44–0.76) | 0.54 (0.40–0.73) | 2.16 (1.97–2.38) | 2.12 (1.88–2.40) |
| Races | | | | |
| White | Ref. | Ref. | Ref. | Ref. |
| Arab | 0.59 (0.36–0.97) | 0.92 (0.54–1.57) | 1.54 (1.29–1.85) | 1.25 (1.00–1.57) |
| Asian | 0.56 (0.29–1.08) | 1.22 (0.62–2.41) | 0.87 (0.64–1.19) | 0.88 (0.60–1.30) |
| Black | 0.93 (0.44–1.96) | 1.50 (0.70–3.19) | 0.64 (0.39–1.06) | 1.07 (0.59–1.97) |

Note: Results are expressed as hazard ratios and 95% confidence intervals (in brackets).

Supplementary Appendix

Coordinator of the RIETE Registry: Manuel Monreal.

RIETE Steering Committee Members: Paolo Prandoni, Benjamin Brenner and Dominique Farge-Bancel.

RIETE National Coordinators: Raquel Barba (Spain), Peter Verhamme (Belgium), Hugo Hyung Bok Yoo (Brazil), Radovan Malý (Czech Republic), Laurent Bertoletti (France), Sebastian Schellong (Germany), Inna Tzoran (Israel), Pierpaolo Di Micco (Italy), Abilio Reis (Portugal), Marijan Bosevski (R. North Macedonia), Lucia Mazzolai (Switzerland), Joseph A. Caprini (USA), Hanh My Bui (Vietnam).

RIETE Registry Coordinating Center: S & H Medical Science Service.

Members of the RIETE Group SPAIN: Adarraga MD, Aibar J, Alberich-Conesa A, Alda-Lozano A, Alfonso J, Amado C, Angelina García M, Arcelus JI, Ballaz A, Barba R, Barbagelata C, Barrón M, Barrón-Andrés B, Bencosme de Méndez EI, Blanco-Molina Á, Bonavila CS, Caballero JC, Cabello-Rojano I, Cantarella R, Cañas-Alcántara I, Carrero R, Castellanos G, Claver G, Crecente P, Criado J, De Juana-Izquierdo C, Del Toro J, Demelo-Rodríguez P, Díaz-Pedroche MC, Díaz-Peromingo JA, Díaz-Simón R, Dubois-Silva Á, Durán D, Escribano JC, Fernández-Bermejo LA, Fernández-Capitán C, Fernández-Reyes JL, Fidalgo MA, Francisco I, Gabara C, Galeano-Valle F, García-Bragado F, García-Coya E, García-Ortega A, Gavín-Sebastián O, Gil-Díaz A, Gómez-Cuervo C, González Martínez JG, González-Munera A, González-Olmedo J, Gorostidi-Álvarez I, Gorostidi-Pérez J, Grau E, Guirado L, Gutiérrez-Guisado J, Hernández-Blasco L, Huélamo-López P, Ibáñez Sustacha IA, Jara-Palomares L, Jiménez D, Jiménez-Morales AI, Jou I, Joya MD, Lalueza A, Llamas P, López-Jiménez L, López-Miguel P, López-Núñez JJ, López-Ruiz A, López-Sáez JB, Lorenzo A, Madridano O, Maestre A, Marchena PJ, Martínez-Prado R, Martín-del Pozo M, Mas Maresma L, Maza JM, Mercado MI, Monreal M, Monzón L, Navas MS, Nieto JA, Núñez Fernández MJ, Olivares MC, Ordieres-Ortega L, Ortiz M, Otálora S, Otero R, Pacheco-Gómez N, Pagán J, Parra-Caballero P, Pedrajas JM, Pérez-Ductor C, Pérez-Pinar M, Peris ML, Pesce ML, Porras JA, Prieto-Gañán LM, Puchades R, Puche G, Rivas A, Rivera-Cívico F, Rivera-Gallego A, Rodríguez-Cobo A, Ruiz-Giménez N, Salgueiro G, Sancho T, Sendín V, Solé A, Soler S, Suárez Fernández S, Tirado R, Tolosa C, Torres MI, Trujillo-Santos J, Uresandi F, Valle R, Varona JF, Vázquez E, Vela-Moreno JR, Vela-Valle L, Vicente-Navarro D, Vidal G, Villalobos A, Villarejo Elena C, Villares P, AUSTRIA: Ay C, Nopp S, Pabinger I, BELGIUM: Van Thillo Q, Verhamme P, Verstraete A, BRAZIL: Yoo HHB, COLOMBIA: Jiménez-Echandía CA, Montenegro AC, Roa J, CZECH REPUBLIC: Hirmerova J, Malý R, FRANCE: Accassat S, Bertoletti L, Bura-Riviere A, Catella J, Chopard R, Espitia O, Mahé I, Morange P, Moustafa F, Plaisance L, Poenou G,

Quéré I, Sarlon-Bartoli G, Suchon P, Versini E, GERMANY: Schellong S, IRAN: Farrashi M, Jenab Y, Khodayari A, Sadeghipour P, Yadangi S, ISRAEL: Brenner B, Dally N, Kenet G, Tzoran I, ITALY: Barillari G, Basaglia M, Bazza A, Bilora F, Bortoluzzi C, Bortoluzzi M, Brandolin B, Ciammaichella MM, Di Micco P, Giorgi-Pierfranceschi M, Imbalzano E, Martini R, Mosanghini ME, Poz A, Prandoni P, Scarinzi P, Simioni P, Siniscalchi C, Taflaj B, Zalunardo B, Visonà A, LATVIA: Kigitovica D, Nemme N, Skride A, MOROCCO: Tazi-Mezalek Z, PORTUGAL: Fonseca S, Marques R, Meireles J, Soeiro B, REPUBLIC OF NORTH MACEDONIA: Bosevski M, Eftimova A, SWITZERLAND: Barco S, Fumagalli RM, Mazzolai L, Wolf S, UK: Aujayeb A, USA: Angiolillo DJ, Caprini JA, Khalil A, Ortega-Paz L, Tafur AJ, Weinberg I, VIETNAM: Bui HM.

ACKNOWLEDGEMENTS We express our gratitude to SANOFI and ROVI for supporting this Registry with an unrestricted educational grant. We also thank the RIETE Registry Coordinating Center, S&H Medical Science Service, for their quality control data, logistic and administrative support and Prof. Salvador Ortiz, Universidad Autónoma de Madrid, Statistical Advisor in S&H Medical Science Service for the statistical analysis of the data presented in this paper. We are thankful to Ann Barlow, PhD, MS for editorial support.

Conflict of Interest Statement: The authors declare no conflicts of interest related to the content of this manuscript